Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...

The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

As more companies are investigating radiopharmaceuticals, the complexities and red tape faced by sponsors are becoming more ...

The grant is set to enhance patient outcomes and quality of life for those with inflammatory bowel disease Credit: Peakstock/Shutterstock. Takeda Canada has co-sponsored the Canadian Inflammatory ...